Lung Cancer

KRAS inhibition comes of age for lung cancer?

A phase 2 study of sotorasib in advanced KRAS p.G12C mutated non-small cell lung cancer has delivered promising results including a disease control rate of 80.6%. Dr Bob Li, from the Memorial Sloan Kettering Cancer Centre in the US, presented the results of CodeBreak 100 at the recent IASLC 2020 World Lung Cancer Conference. The ...

Already a member?

Login to keep reading.

© 2021 the limbic